SRL
NTLA icon

Scientech Research LLC’s Intellia Therapeutics NTLA Stock Holding History

Scientech Research LLC’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Sell
16,265
-2,301
-12% -$29.3K 0.17% 232
2025
Q4 		$167K Sell
18,566
-9,521
-34% -$131K 0.11% 365
2025
Q3 		$485K Buy
+28,087
New +$346K 0.17% 260
2024
Q4 		– Sell
-39,262
Closed -$807K – 770
2024
Q3 		$807K Sell
39,262
-7,839
-17% -$181K 0.16% 255
2024
Q2 		$1.05M Buy
47,101
+26,884
+133% +$640K 0.22% 170
2024
Q1 		$556K Buy
20,217
+9,776
+94% +$272K 0.29% 118
2023
Q4 		$318K Buy
+10,441
New +$300K 0.32% 109

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return